Advertisement

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Sep
17
Today In Oncology
What Constitutes Clinical Expertise in an AI-Enabled Era
American Cancer Society Urges Men to Understand Their Risk for Prostate Cancer
Two Phase III Trials Explore B7-H3–Directed ADCs in Relapsed SCLC
ADC/Immunotherapy Combination Shows Activity in Treatment-Resistant Nasopharyngeal Carcinoma
Long-Term Benefit Seen With Adjuvant Osimertinib in EGFR-Mutated NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo